Business
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo
About this update from Crinetics Pharmaceuticals, Inc.
[{"type":"text","content":"83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p","length":104,"tagName":"div"}]